Black Diamond Therapeutics, Inc.

BDTX Healthcare Biotechnology

Black Diamond Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.0 million. In the quarter to June 2026, EPS grew 10.5% and free cash flow grew 12.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

1.72 0.02 −1.15%
Market cap
$100.0M
P/E
0.0×
Fwd P/E
−3.0×
Dividend yield
—
F-score
n/a
Altman Z
−0.10
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
7.28 8.46 8.42 8.94
Net Debt/EBITDA
9.19 10.53 7.33 12.44
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.14) (0.18) (0.12) (0.14)
Book value per Share
1.68 1.82 1.97 2.22
Free Cash Flow
(7.97) (10.23) (6.78) (7.85)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates